{"id":"https://openalex.org/W2061908201","doi":"https://doi.org/10.1158/1078-0432.ccr-12-2502","title":"Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials","display_name":"Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials","publication_year":2013,"publication_date":"2013-01-09","ids":{"openalex":"https://openalex.org/W2061908201","doi":"https://doi.org/10.1158/1078-0432.ccr-12-2502","mag":"2061908201","pmid":"https://pubmed.ncbi.nlm.nih.gov/23303214"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.ccr-12-2502","doi":"https://doi.org/10.1158/1078-0432.ccr-12-2502","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-12-2502","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112905044","display_name":"Roger Sidhu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Roger Sidhu","raw_affiliation_strings":["Authors' Affiliations:\u20081Clinical Development; 2Biostatistics, Amgen Inc., Thousand Oaks; and 3Biostatistics, Amgen Inc., South San Francisco, California","Biostatistics, Amgen Inc., Thousand Oaks"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Clinical Development; 2Biostatistics, Amgen Inc., Thousand Oaks; and 3Biostatistics, Amgen Inc., South San Francisco, California","institution_ids":["https://openalex.org/I1320553840"]},{"raw_affiliation_string":"Biostatistics, Amgen Inc., Thousand Oaks","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031650686","display_name":"Alan Rong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alan Rong","raw_affiliation_strings":["Authors' Affiliations:\u20081Clinical Development; 2Biostatistics, Amgen Inc., Thousand Oaks; and 3Biostatistics, Amgen Inc., South San Francisco, California","Biostatistics, Amgen Inc., Thousand Oaks"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Clinical Development; 2Biostatistics, Amgen Inc., Thousand Oaks; and 3Biostatistics, Amgen Inc., South San Francisco, California","institution_ids":["https://openalex.org/I1320553840"]},{"raw_affiliation_string":"Biostatistics, Amgen Inc., Thousand Oaks","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108408583","display_name":"Steve Dahlberg","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steve Dahlberg","raw_affiliation_strings":["Authors' Affiliations:\u20081Clinical Development; 2Biostatistics, Amgen Inc., Thousand Oaks; and 3Biostatistics, Amgen Inc., South San Francisco, California","Biostatistics, Amgen Inc., Thousand Oaks"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Clinical Development; 2Biostatistics, Amgen Inc., Thousand Oaks; and 3Biostatistics, Amgen Inc., South San Francisco, California","institution_ids":["https://openalex.org/I1320553840"]},{"raw_affiliation_string":"Biostatistics, Amgen Inc., Thousand Oaks","institution_ids":["https://openalex.org/I1320553840"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5112905044"],"corresponding_institution_ids":["https://openalex.org/I1320553840"],"apc_list":null,"apc_paid":null,"fwci":4.6313,"has_fulltext":false,"cited_by_count":55,"citation_normalized_percentile":{"value":0.95840502,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"19","issue":"5","first_page":"969","last_page":"976"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.9854000210762024,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.9854000210762024,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10335","display_name":"Colorectal Cancer Surgical Treatments","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8740000128746033},{"id":"https://openalex.org/keywords/surrogate-endpoints","display_name":"surrogate endpoints","score":0.7820000052452087},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9919999837875366},{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.9940000176429749},{"id":"https://openalex.org/keywords/chemotherapy","display_name":"chemotherapy","score":0.45399999618530273},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.9269999861717224},{"id":"https://openalex.org/keywords/fluoropyrimidine","display_name":"fluoropyrimidine","score":0.6819999814033508},{"id":"https://openalex.org/keywords/panitumumab","display_name":"panitumumab","score":0.9419999718666077},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/aflibercept","display_name":"aflibercept","score":0.9980000257492065},{"id":"https://openalex.org/keywords/egfr-inhibitors","display_name":"EGFR inhibitors","score":0.9120000004768372},{"id":"https://openalex.org/keywords/response-rate","display_name":"response rate","score":0.875}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8258616924285889},{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.752392053604126},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.736380934715271},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.723514199256897},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7219549417495728},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.7008138298988342},{"id":"https://openalex.org/C2778332735","wikidata":"https://www.wikidata.org/wiki/Q417775","display_name":"Panitumumab","level":5,"score":0.6784401535987854},{"id":"https://openalex.org/C141341695","wikidata":"https://www.wikidata.org/wiki/Q2368661","display_name":"Surrogate endpoint","level":2,"score":0.5812786817550659},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5615395903587341},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.5426540374755859},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5258708000183105},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3987063765525818},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.39095622301101685}],"mesh":[{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012196","descriptor_name":"Review Literature as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":false},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.ccr-12-2502","doi":"https://doi.org/10.1158/1078-0432.ccr-12-2502","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-12-2502","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},{"id":"pmid:23303214","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23303214","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Evaluation Study"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Systematic Review","id":"https://openalex.org/study-designs/systematic-review"},{"display_name":"Meta-Analysis","id":"https://openalex.org/study-designs/meta-analysis"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320324142","display_name":"European Society for Medical Oncology","ror":"https://ror.org/03xtz2n86"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":48,"referenced_works":["https://openalex.org/W255679108","https://openalex.org/W1969065847","https://openalex.org/W1991276289","https://openalex.org/W2002226820","https://openalex.org/W2016901953","https://openalex.org/W2044792687","https://openalex.org/W2085705101","https://openalex.org/W2092238717","https://openalex.org/W2095201384","https://openalex.org/W2096310679","https://openalex.org/W2096491867","https://openalex.org/W2098354753","https://openalex.org/W2101509326","https://openalex.org/W2104580737","https://openalex.org/W2106789440","https://openalex.org/W2106845199","https://openalex.org/W2115366398","https://openalex.org/W2115407830","https://openalex.org/W2121368761","https://openalex.org/W2123202734","https://openalex.org/W2123811123","https://openalex.org/W2125447919","https://openalex.org/W2126133903","https://openalex.org/W2127640925","https://openalex.org/W2129255527","https://openalex.org/W2133399075","https://openalex.org/W2134933569","https://openalex.org/W2136055188","https://openalex.org/W2138154121","https://openalex.org/W2139168548","https://openalex.org/W2142257518","https://openalex.org/W2143743735","https://openalex.org/W2151049934","https://openalex.org/W2154399935","https://openalex.org/W2155949904","https://openalex.org/W2156147330","https://openalex.org/W2156596904","https://openalex.org/W2156700619","https://openalex.org/W2157769714","https://openalex.org/W2158850140","https://openalex.org/W2161664263","https://openalex.org/W2162313061","https://openalex.org/W2166396356","https://openalex.org/W2166602936","https://openalex.org/W2167422856","https://openalex.org/W2172116130","https://openalex.org/W2314927739","https://openalex.org/W4240703051"],"related_works":["https://openalex.org/W2154399935","https://openalex.org/W1981432812","https://openalex.org/W2589714665","https://openalex.org/W2161664263","https://openalex.org/W2557007274","https://openalex.org/W2339228323","https://openalex.org/W2803670008","https://openalex.org/W2947340845","https://openalex.org/W2143427907","https://openalex.org/W4406869753"],"abstract_inverted_index":{"Pooled":[0],"analyses":[1],"of":[2,34,45,49,60,95,103,118,144,158,166,195,199],"chemotherapy":[3,35,50,200],"trials":[4,48,76,83,143,157,165,198],"in":[5,36,147,205,212,229],"metastatic":[6],"colorectal":[7],"cancer":[8],"(mCRC)":[9],"have":[10],"suggested":[11],"that":[12,77,216],"progression-free":[13],"survival":[14,22],"(PFS)":[15],"is":[16],"a":[17,100,219],"surrogate":[18,221],"endpoint":[19,222],"for":[20,66,135,139,152,163,223],"overall":[21],"(OS).":[23],"However,":[24],"this":[25,192],"has":[26],"not":[27],"been":[28],"evaluated":[29,78],"under":[30],"current":[31,226],"standard-of-care":[32],"regimens":[33,80,228],"combination":[37,148],"with":[38,85,99,122,149,210,225],"targeted":[39,52,86,145,159,202],"therapies.":[40],"We":[41],"conducted":[42,84],"an":[43],"analysis":[44,110,194],"published":[46],"mCRC":[47,75,197,231],"and":[51,62,81,91,120,130,161,176,186,201],"therapies":[53],"from":[54,72],"2000":[55],"to":[56,114],"evaluate":[57],"the":[58,116,230],"surrogacy":[59],"PFS":[61,119,128,184,206,217],"response":[63],"rate":[64],"(RR)":[65],"OS.":[67,123,213],"Study-level":[68],"data":[69],"was":[70,106,111,133],"pooled":[71],"24":[73],"randomized":[74,196],"fluoropyrimidine-based":[79],"included":[82],"agents":[87,146],"(panitumumab,":[88],"cetuximab,":[89],"bevacizumab,":[90],"aflibercept).":[92],"A":[93],"total":[94],"69":[96],"treatment":[97,227],"arms":[98],"sample":[101],"size":[102],"20,438":[104],"patients":[105],"included.":[107],"Linear":[108],"regression":[109],"carried":[112],"out":[113],"estimate":[115],"correlation":[117,125,172],"RR":[121,175],"The":[124],"coefficient":[126],"between":[127,174,183],"HRs":[129,132,178,185,188],"OS":[131,177,187,224],"0.86":[134],"all":[136,170],"trials,":[137],"0.89":[138],"12":[140],"phase":[141,155],"III":[142,156],"chemotherapy,":[150],"0.95":[151],"8":[153],"first-line":[154],"agents,":[160,203],"0.83":[162],"9":[164],"anti-EGFR-targeted":[167],"agents.":[168],"In":[169,191],"cases,":[171],"coefficients":[173],"were":[179],"lower":[180],"than":[181],"those":[182],"(range,":[189],"0.42-0.81).":[190],"study-level":[193],"improvements":[204,211],"are":[207],"strongly":[208],"correlated":[209],"This":[214],"suggests":[215],"remains":[218],"valid":[220],"setting.":[232]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":7},{"year":2014,"cited_by_count":10},{"year":2013,"cited_by_count":6}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}